Kailera Therapeutics Oral Ribupatide Expansion Shows Promising Trial Data In February, Hengrui Pharma and Kailera Therapeutics released topline data from Hengrui's Phase 2 trial of once-daily oral ribupatide in Chinese patients. On Thursday, Kailera Therapeutics Inc. (NASDAQ:KLRA) priced its initial public offering of 39.06 million shares at $16.00 per share, with gross proceeds of around $625 million. In addition, Kailera has granted the underwriters an option to purchase up to an additional 5.86 million s ...